Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, LQDA, ETON, RYTM, APGE, and represent 51.36% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: CBIO (+$14M), ACOG (+$13M), RZLT (+$13M), SLGL (+$11M), KPTI (+$6.8M), JBIO (+$6.6M), URGN (+$6.3M), CATX, VYGR, RLMD.
- Started 21 new stock positions in GBIO, RAPT, FBIO, JBIO, BBIO, KPTI, STRO, TECX, QTTB, RLMD. CBIO, RCKT, MGTX, AVIR, URGN, SLN, Assertio Holdings, VTYX, CATX, VYGR, ENTA.
- Reduced shares in these 10 stocks: IMNM (-$37M), RYTM (-$14M), SRPT (-$11M), LRMR (-$11M), CDXS (-$9.8M), ARVN (-$8.4M), LQDA (-$6.3M), TMCI, Karyopharm Therapeutics Inc note 3.000%10/1, ADCT.
- Sold out of its positions in SYRE, ARVN, IBIO, IMNM, Karyopharm Therapeutics Inc note 3.000%10/1, LRMR, PEPG, SRPT, TMCI, ADCT.
- Opaleye Management was a net buyer of stock by $7.2M.
- Opaleye Management has $758M in assets under management (AUM), dropping by 7.16%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 54 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 25.2 | $191M | 3.9M | 49.00 |
|
|
| Liquidia Corporation Com New (LQDA) | 11.2 | $85M | -6% | 2.4M | 34.90 |
|
| Eton Pharmaceuticals (ETON) | 6.4 | $48M | 2.9M | 16.91 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 4.7 | $35M | -28% | 330k | 107.04 |
|
| Apogee Therapeutics (APGE) | 3.9 | $29M | +6% | 388k | 75.48 |
|
| Sanuwave Health (SNWV) | 3.9 | $29M | 981k | 29.84 |
|
|
| Stoke Therapeutics (STOK) | 2.9 | $22M | 695k | 31.74 |
|
|
| Ocular Therapeutix (OCUL) | 2.6 | $19M | 1.6M | 12.14 |
|
|
| Sol Gel Technologies Shs New (SLGL) | 2.5 | $19M | +121% | 454k | 42.14 |
|
| Cg Oncology (CGON) | 2.2 | $17M | 410k | 41.52 |
|
|
| Tg Therapeutics (TGTX) | 2.1 | $16M | 535k | 29.81 |
|
|
| Disc Medicine (IRON) | 2.1 | $16M | +3% | 200k | 79.41 |
|
| Rezolute Com New (RZLT) | 2.0 | $15M | +595% | 6.3M | 2.36 |
|
| Crescent Biopharma (CBIO) | 1.8 | $14M | NEW | 1.2M | 11.86 |
|
| Alkermes SHS (ALKS) | 1.8 | $14M | +8% | 490k | 27.98 |
|
| Alpha Cognition Com New (ACOG) | 1.8 | $14M | +1698% | 2.1M | 6.50 |
|
| Annexon (ANNX) | 1.7 | $13M | 2.6M | 5.02 |
|
|
| Edgewise Therapeutics (EWTX) | 1.6 | $12M | 500k | 24.82 |
|
|
| Codexis (CDXS) | 1.5 | $11M | -46% | 6.8M | 1.63 |
|
| Protagonist Therapeutics (PTGX) | 1.2 | $9.2M | 105k | 87.34 |
|
|
| Gossamer Bio (GOSS) | 1.1 | $8.4M | 2.7M | 3.10 |
|
|
| Mbx Biosciences (MBX) | 1.1 | $8.2M | +2% | 260k | 31.54 |
|
| Revolution Medicines (RVMD) | 1.1 | $8.0M | 100k | 79.65 |
|
|
| Xoma Corp Del Com New (XOMA) | 1.0 | $7.8M | +14% | 293k | 26.59 |
|
| Journey Med Corp (DERM) | 1.0 | $7.5M | 975k | 7.71 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 0.9 | $6.8M | NEW | 930k | 7.36 |
|
| Jade Biosciences Com New (JBIO) | 0.9 | $6.6M | NEW | 428k | 15.43 |
|
| Urogen Pharma (URGN) | 0.8 | $6.3M | NEW | 268k | 23.42 |
|
| Alumis (ALMS) | 0.7 | $5.2M | -19% | 535k | 9.76 |
|
| Perspective Therapeutics (CATX) | 0.7 | $5.0M | NEW | 1.2M | 4.21 |
|
| Voyager Therapeutics (VYGR) | 0.6 | $4.7M | NEW | 1.2M | 3.93 |
|
| Relmada Therapeutics (RLMD) | 0.6 | $4.5M | NEW | 935k | 4.83 |
|
| Tectonic Therapeutic (TECX) | 0.6 | $4.5M | NEW | 215k | 20.86 |
|
| Protalix Biotherapeutics (PLX) | 0.6 | $4.5M | -3% | 2.5M | 1.80 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $4.3M | -11% | 345k | 12.52 |
|
| Fortress Biotech Com New (FBIO) | 0.5 | $4.0M | NEW | 1.1M | 3.66 |
|
| Rocket Pharmaceuticals (RCKT) | 0.4 | $3.4M | NEW | 955k | 3.51 |
|
| Meiragtx Holdings (MGTX) | 0.4 | $3.1M | NEW | 391k | 7.95 |
|
| Rigel Pharmaceuticals (RIGL) | 0.4 | $3.0M | +85% | 70k | 42.83 |
|
| Zymeworks Del (ZYME) | 0.4 | $2.9M | +8% | 109k | 26.33 |
|
| Assertio Holdings Com New | 0.3 | $2.6M | NEW | 285k | 9.07 |
|
| Ventyx Biosciences (VTYX) | 0.3 | $2.3M | NEW | 252k | 9.03 |
|
| Ocuphire Pharma (IRD) | 0.3 | $2.3M | 1.1M | 2.01 |
|
|
| Sutro Biopharma Com Shs (STRO) | 0.3 | $2.2M | NEW | 191k | 11.57 |
|
| Cabaletta Bio (CABA) | 0.3 | $2.0M | +11% | 900k | 2.19 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.2 | $1.9M | +342% | 1.4M | 1.35 |
|
| Generation Bio Com New (GBIO) | 0.2 | $1.8M | NEW | 310k | 5.68 |
|
| Bridgebio Pharma (BBIO) | 0.2 | $1.4M | NEW | 18k | 76.49 |
|
| Enanta Pharmaceuticals (ENTA) | 0.2 | $1.2M | NEW | 75k | 15.77 |
|
| Q32 Bio (QTTB) | 0.1 | $708k | NEW | 213k | 3.32 |
|
| Atea Pharmaceuticals (AVIR) | 0.1 | $642k | NEW | 180k | 3.57 |
|
| Silence Therapeutics Ads (SLN) | 0.1 | $480k | NEW | 79k | 6.08 |
|
| Rapt Therapeutics Com New (RAPT) | 0.0 | $213k | NEW | 150k | 1.42 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $115k | 111k | 1.04 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2025 Q4 filed Feb. 17, 2026
- Opaleye Management 2025 Q3 filed Nov. 14, 2025
- Opaleye Management 2025 Q2 restated filed Aug. 15, 2025
- Opaleye Management 2025 Q1 filed May 15, 2025
- Opaleye Management 2024 Q4 filed Feb. 14, 2025
- Opaleye Management 2024 Q3 filed Nov. 14, 2024
- Opaleye Management 2024 Q2 filed Aug. 14, 2024
- Opaleye Management 2024 Q1 restated filed May 29, 2024
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022